Diabetes Therapeutics Market Key Factors, Current Trends Analysis, Business Overview Analysis 2027


"Diabetes Therapeutics Market : Global Opportunity Analysis and Industry Forecast, 2017-2023," the global diabetes therapeutics market was valued at $66,993 million in 2016, and is estimated to reach $186,842 million by 2023, growing at a CAGR of 16.0% from 2017 to 2023.

The major factor that contributes to the market growth are increase in incidence rate of diabetes caused by rapid urbanization and sedentary lifestyle. Moreover, development of affordable & effective diabetes therapeutics, rise in obese population, consumption of fast food, growth in awareness among people about self-management of diabetes, and support from the government further boost the market growth. However, side effects of diabetic drugs on patients and stringent approval process for these drugs hinder this growth. Moreover, rise in awareness about diabetes care and untapped market opportunities in developing regions are expected to provide numerous opportunities for market growth.

Read More@ https://www.prnewswire.com/news-releases/global-diabetes-therapeutics-market-expected-to-reach-186842-million-by-2023---allied-market-research-650408233.html


The injectables segment is expected to maintain its dominant position during the analysis period, owing to rise in the prevalence of diabetes, increase in geriatric population, high demand of self-care, and increased awareness about use of insulin (one of the injectables) as an anti-diabetic drug.

North America accounted for more than one-third share of the global market in 2016, and is expected to remain dominant throughout the forecast period. This is attributed to the increase in incidence of diabetes, growth in geriatric population, and adoption of sedentary lifestyle of people that leads to diabetes. In addition, presence of highly sophisticated healthcare infrastructure is expected to present new growth opportunities to the players in this market.

The major companies profiled in the report include AstraZeneca plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Novo Nordisk, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Comments

Post a Comment

Popular posts from this blog

Technology of Artificial Breeding of Aquaculture Species in the Hatcheries across the World.

Image
"Artificial fish breeding is such a process by which minnow are produced artificially. The steps and method of artificial breeding of fish are described below.Collecting Pituitary Gland Pituitary gland is a very important gland of fish. It is one type of endocrine glands. " The hormones secreted from pituitary gland control the tasks of this types of other glands. Growth hormone and gonadotropin hormone among the all secreted hormone from pituitary gland influence the growth and tasks of sexual organs. Pituitary gland used as catalyst and inducing agent for artificial breeding of fish. This gland is located under brain. Download Free PDF File@  https://bit.ly/2UNsdgP The important role of aquaculture (pisciculture) is demonstrated using data on development of the world fishery. It is noted that the present-day level of harvesting biological resources of the World Ocean has reached its upper limit. Against this background, the proportion of the global fish
Read more